Semaglutide

Summary

Semaglutide is an approved glucagon‑like peptide‑1 (GLP‑1) receptor agonist formulated as a once‑weekly subcutaneous injection and as an oral tablet. It is indicated for type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity, with or without diabetes. Clinical trials have demonstrated substantial reductions in body weight and improvements in cardiometabolic risk factors, while the most frequent adverse events are gastrointestinal in nature.

Mechanism of Action

Semaglutide binds the GLP‑1 receptor, a G‑protein‑coupled receptor on pancreatic β‑cells, α‑cells, gastric motility centers and hypothalamic appetite circuits. Receptor activation enhances glucose‑dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, reducing post‑prandial glucose excursions. In the central nervous system it attenuates appetite by influencing neuropeptide Y and pro‑opiomelanocortin pathways. The peptide is engineered to resist dipeptidyl peptidase‑4 degradation, providing a prolonged half‑life that supports once‑weekly dosing.

What the Research Shows

Multiple phase 3 trials have evaluated semaglutide for weight management. In the STEP 1 trial (n=1961, obesity without diabetes) a 2.4 mg weekly dose produced a mean 14.9% weight loss versus 2.4% with placebo over 68 weeks, with 86% achieving ≥5% loss. STEP 2 (overweight/obesity with type 2 diabetes) showed a 9.6% reduction versus placebo. A meta‑analysis of four obesity trials (3,613 participants) reported an average 11.9% weight reduction. Network meta‑analysis across 76 GLP‑1RA trials confirmed semaglutide’s efficacy in lowering HbA1c, fasting glucose, LDL‑C and total cholesterol. Comparative data from SURMOUNT‑5 indicated tirzepatide achieved greater weight loss than semaglutide, suggesting relative potency differences. An extension study documented partial weight regain after drug discontinuation.

Reported Benefits

Semaglutide consistently produces clinically meaningful weight loss, ranging from roughly 10% to 15% of baseline body weight in adults with obesity, with or without diabetes. It also improves glycaemic control, lowers HbA1c, reduces fasting glucose, and modestly decreases LDL‑C and total cholesterol. Participants report enhanced physical functioning and reductions in waist circumference. These effects translate into better cardiometabolic risk profiles, supporting its use as a pharmacologic adjunct to lifestyle modification.

Limitations of the Evidence

Head‑to‑head data show tirzepatide may achieve larger weight reductions than semaglutide, indicating semaglutide is not the most potent option currently available. Most efficacy data derive from trials lasting up to 72 weeks; longer‑term durability is less certain, with extension studies indicating some weight regain after cessation. Evidence is largely confined to controlled trial settings, and real‑world effectiveness data are limited. Safety concerns, particularly gastrointestinal adverse events, may limit tolerability for some patients.

Safety Considerations

The most common adverse events are nausea, vomiting, diarrhoea and constipation, typically mild to moderate and transient, but they lead to discontinuation in about 4–5% of participants. Meta‑analyses report a 1.5‑fold higher risk of gastrointestinal events and a roughly two‑fold higher risk of treatment discontinuation compared with placebo. Serious adverse events, including acute pancreatitis and gallbladder disease, occur at a modestly increased frequency. Caution is advised in individuals with a history of pancreatitis, gallstones, or severe gastrointestinal disorders, and monitoring is recommended during dose escalation.

How It Is Administered

Semaglutide is administered either as a once‑weekly subcutaneous injection (commonly 2.4 mg for obesity) or as a daily oral tablet. In clinical studies, dosing began at a low level and was gradually increased to the target dose to improve tolerability. The injection is given under the skin of the abdomen, thigh or upper arm, while the oral formulation is taken on an empty stomach with a small amount of water, followed by a waiting period before food or other medicines.

Routes of Administration

Goals & Uses

• Non-alcoholic steatohepatitis (NASH)HepaticModerate
• Cardiovascular risk reductionCardiovascularHigh
• Weight lossMetabolicHighChronic weight management and appetite reduction
• Glycemic controlDiabetesHigh
• Chronic weight management / obesityWeight ManagementHigh
• Weight reductionMetabolicHigh
• Glycemic control in type 2 diabetesMetabolicHigh
• Kidney disease risk reduction in T2DMRenalModerate
• Appetite suppression / satietyMetabolicHigh

Contraindications

• Diabetic ketoacidosisMetabolicHigh
• Personal or family history of medullary thyroid carcinoma (MTC)OncologicHigh
• Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
• Medullary thyroid carcinoma (MTC)OncologyHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• History of serious hypersensitivity to semaglutideImmunologicHigh
• Multiple endocrine neoplasia type 2 (MEN2)OncologyHigh

Adverse Effects

• PancreatitisGastrointestinalRareInflammation of the pancreas
• Injection site reactionsLocalUncommon
• Diabetic retinopathy complicationsOphthalmologicUncommon
• ConstipationGastrointestinalCommonReduced bowel frequency or difficulty passing stool
• Hypoglycaemia (with insulin or sulfonylureas)MetabolicUncommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• Acute pancreatitisGastrointestinalRare
• Gallbladder diseaseHepatobiliaryRareGallstones, cholecystitis, or biliary complications
• DiarrheaGastrointestinalCommonLoose or frequent stools

Drug Interactions

• InsulinModerateMay increase risk of low blood sugar
• Oral medications (general)Low
• WarfarinModerate
• Oral medications with narrow absorption windowLow
• Oral contraceptives (estrogen‑containing)Low
• SulfonylureasModerateMay increase risk of low blood sugar
• Insulin / Insulin secretagogues (sulfonylureas)High

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patients (<18 years)AgeRelative
• Pediatric patients (<18 y)AgeAbsolute
• Severe renal impairment / End-stage renal diseaseRenalRelative
• History of pancreatitisGastrointestinalRelative
• Pregnant womenReproductiveRelative
• Severe hepatic impairmentOrgan ImpairmentRelative
• Severe renal impairment (eGFR <30 mL/min/1.73 m²)RenalRelative
• Pregnancy and lactationReproductiveAbsolute

Regulatory Status

• European UnionApprovedApproved: type 2 diabetes, obesity
• United StatesApprovedApproved: type 2 diabetes, obesityOzempic (SC), Rybelsus (oral), Wegovy (SC)
• United KingdomApprovedApproved: type 2 diabetes, obesity

Approved in the US, EU and UK for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Cardiovascular outcomes trial demonstrated MACE reduction.

Evidence & Sources

• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
  Journal ArticleModerateAronne LJ, et al.2025-01-01T00:00:00.000000Z
• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
  Journal ArticleModerateDavies M, et al.2021-01-01T00:00:00.000000Z
• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
  Journal ArticleHighYao H, et al.2024-01-01T00:00:00.000000Z
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
  Journal ArticleHighTan HC, Dampil OA, Marquez MM2022-01-01T00:00:00.000000Z
• Once-Weekly Semaglutide in Adults with Overweight or Obesity
  Journal ArticleModerateWilding JPH, et al.2021-01-01T00:00:00.000000Z
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
  Journal ArticleModerateWilding JPH, et al.2022-01-01T00:00:00.000000Z

Frequently Asked Questions